David O'Neal

List of Publications by Year
in descending order

74 papers	2,482 citations	257101 24 h-index	214527 47 g-index
76 all docs	76 docs citations	76 times ranked	2531 citing authors

#	Article	IF	Citations
1	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. Journal of Diabetes Science and Technology, 2023, 17, 1226-1242.	1.3	69
2	Strengths and Challenges of Closed-Loop Insulin Delivery During Exercise in People With Type 1 Diabetes: Potential Future Directions. Journal of Diabetes Science and Technology, 2023, 17, 1077-1084.	1.3	4
3	Comparable Glucose Control with Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System During Exercise. Diabetes Technology and Therapeutics, 2022, 24, 93-101.	2.4	12
4	A Randomized Crossover Trial Comparing Glucose Control During Moderate-Intensity, High-Intensity, and Resistance Exercise With Hybrid Closed-Loop Insulin Delivery While Profiling Potential Additional Signals in Adults With Type 1 Diabetes. Diabetes Care, 2022, 45, 194-203.	4.3	24
5	Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial. Diabetes Care, 2022, 45, 381-390.	4.3	43
6	Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2221-e2236.	1.8	60
7	Integrating Multiple Inputs Into an Artificial Pancreas System: Narrative Literature Review. JMIR Diabetes, 2022, 7, e28861.	0.9	8
8	Upload and Review of Insulin Pump and Glucose Sensor Data by Adults with Type 1 Diabetes: A Clinic Audit. Diabetes Technology and Therapeutics, 2022, 24, 531-534.	2.4	2
9	Feasibility study of a prototype extendedâ€wear insulin infusion set in adults with type 1 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 1143-1149.	2.2	7
10	Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During Journeys. Diabetes Technology and Therapeutics, 2022, 24, 350-356.	2.4	1
11	The Potential of Current Noninvasive Wearable Technology for the Monitoring of Physiological Signals in the Management of Type 1 Diabetes: Literature Survey. Journal of Medical Internet Research, 2022, 24, e28901.	2.1	5
12	Closed-Loop Insulin Delivery Effects on Glycemia During Sleep and Sleep Quality in Older Adults with Type 1 Diabetes: Results from the ORACL Trial. Diabetes Technology and Therapeutics, 2022, 24, 666-671.	2.4	8
13	Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections. Diabetes Technology and Therapeutics, 2021, 23, 460-466.	2.4	7
14	Severe acute respiratory syndrome coronavirus 2 as a potential cause of type 1 diabetes facilitated by spike protein receptor binding domain attachment to human islet cells: An illustrative case study and experimental data. Diabetic Medicine, 2021, 38, e14608.	1.2	9
15	Insulin micro-secretion in Type 1 diabetes and related microRNA profiles. Scientific Reports, 2021, 11, 11727.	1.6	16
16	First Randomized Controlled Trial of Hybrid Closed Loop Versus Multiple Daily Injections or Insulin Pump Using Self-Monitoring of Blood Glucose in Free-Living Adults with Type 1 Diabetes Undertaking Exercise. Journal of Diabetes Science and Technology, 2021, 15, 1399-1401.	1.3	9
17	Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System in Adults With Type 1 Diabetes: A Randomized, Open-Label, Crossover Trial. Diabetes Care, 2021, 44, 2371-2378.	4.3	22
18	â€˜Is Insulin Right for Me?â€™ Development of a theory-informed, web-based resource for reducing psychological barriers to insulin therapy in type 2 diabetes. BMJ Open, 2021, 11, e045853.	0.8	4

#	Article	IF	Citations
19	Impact of quarterly professional-mode flash glucose monitoring in adults with type 2 diabetes in general practice (GP-OSMOTIC): Secondary psychological and self-care outcomes of a pragmatic, open-label, 12-month, randomised controlled trial. Diabetes Research and Clinical Practice, 2021, 179, 108994.	1.1	0
20	Meal-time glycaemia in adults with type 1 diabetes using multiple daily injections vs insulin pump therapy following carbohydrate-counting education and bolus calculator provision. Diabetes Research and Clinical Practice, 2021, 179, 109000.	1.1	3
21	Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents With Type 1 Diabetes. JAMA Pediatrics, 2021, 175, 1227.	3.3	54
22	Costâ€effectiveness of professionalâ€mode flash glucose monitoring in general practice among adults with type 2 diabetes: Evidence from the GPâ€OSMOTIC trial. Diabetic Medicine, 2021, , e14747.	1.2	1
23	Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 17-26.	5.5	30
24	Glucose and Counterregulatory Responses to Exercise in Adults With Type 1 Diabetes and Impaired Awareness of Hypoglycemia Using Closed-Loop Insulin Delivery: A Randomized Crossover Study. Diabetes Care, 2020, 43, 480-483.	4.3	19
25	Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital Consensus Guideline. Journal of Diabetes Science and Technology, 2020, 14, 1035-1064.	1.3	77
26	Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial. Diabetes Care, 2020, 43, 3024-3033.	4.3	85
27	Estimated insulin sensitivity in Type 1 diabetes adults using clinical and research biomarkers. Diabetes Research and Clinical Practice, 2020, 167, 108359.	1.1	12
28	Multimorbidity, glycaemic variability and time in target range in people with type 2 diabetes: A baseline analysis of the GP-OSMOTIC trial. Diabetes Research and Clinical Practice, 2020, 169, 108451.	1.1	2
29	COVID-19, Type 1 Diabetes Clinical Practice, Research, and Remote Medical Care: A View From the Land Down-Under. Journal of Diabetes Science and Technology, 2020, 14, 803-804.	1.3	11
30	Glucose Control During Physical Activity and Exercise Using Closed Loop Technology in Adults and Adolescents with Type 1 Diabetes. Canadian Journal of Diabetes, 2020, 44, 740-749.	0.4	46
31	Guiding Glucose Management Discussions Among Adults With Type 2 Diabetes in General Practice: Development and Pretesting of a Clinical Decision Support Tool Prototype Embedded in an Electronic Medical Record. JMIR Formative Research, 2020, 4, e17785.	0.7	5
32	Glucose Control in Adults with Type 1 Diabetes Using a Medtronic Prototype Enhanced-Hybrid Closed-Loop System: A Feasibility Study. Diabetes Technology and Therapeutics, 2019, 21, 499-506.	2.4	25
33	HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment. BMJ Open, 2019, 9, e033059.	0.8	16
34	Glucose Control Using a Standard Versus an Enhanced Hybrid Closed Loop System: A Randomized Crossover Study. Diabetes Technology and Therapeutics, 2019, 21, 56-58.	2.4	22
35	The Clinical Case for the Integration of a Ketone Sensor as Part of a Closed Loop Insulin Pump System. Journal of Diabetes Science and Technology, 2019, 13, 967-973.	1.3	14
36	Continuous glucose monitoring: a review of the evidence, opportunities for future use and ongoing challenges. Internal Medicine Journal, 2018, 48, 499-508.	0.5	43

#	Article	IF	Citations
37	Suboptimal behaviour and knowledge regarding overnight glycaemia in adults with type 1 diabetes is common. Internal Medicine Journal, 2018, 48, 1080-1086.	0.5	6
38	Impact of multimorbidity count on all-cause mortality and glycaemic outcomes in people with type 2 diabetes: a systematic review protocol. BMJ Open, 2018, 8, e021100.	0.8	5
39	Lipidâ€lowering therapy use and achievement of cholesterol targets in an Australian diabetes clinic. Internal Medicine Journal, 2018, 48, 201-204.	0.5	1
40	Associations between multimorbidity, all-cause mortality and glycaemia in people with type 2 diabetes: A systematic review. PLoS ONE, 2018, 13, e0209585.	1.1	32
41	GP-OSMOTIC trial protocol: an individually randomised controlled trial to determine the effect of retrospective continuous glucose monitoring (r-CGM) on HbA1c in adults with type 2 diabetes in general practice. BMJ Open, 2018, 8, e021435.	0.8	8
42	Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial. Diabetologia, 2018, 61, 1918-1922.	2.9	14
43	Effect of 6 months hybrid closed-loop insulin delivery in young people with type 1 diabetes: a randomised controlled trial protocol. BMJ Open, 2018, 8, e020275.	0.8	11
44	Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol. BMJ Open, 2018, 8, e020274.	0.8	7
45	Predictors of insulin uptake among adults with type 2 diabetes in the Stepping Up Study. Diabetes Research and Clinical Practice, 2017, 133, 204-210.	1.1	8
46	Moving Toward a Unified Platform for Insulin Delivery and Sensing of Inputs Relevant to an Artificial Pancreas. Journal of Diabetes Science and Technology, 2017, 11, 308-314.	1.3	9
47	Lixisenatide reduces glycaemic variability in insulinâ€treated patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1317-1321.	2.2	11
48	Asymmetric changes in circulating insulin levels after an increase compared with a reduction in insulin pump basal rate in people with Type 1 diabetes. Diabetic Medicine, 2017, 34, 1158-1164.	1.2	2
49	Closed-Loop Insulin Delivery for Adults with Type 1 Diabetes Undertaking High-Intensity Interval Exercise Versus Moderate-Intensity Exercise: A Randomized, Crossover Study. Diabetes Technology and Therapeutics, 2017, 19, 340-348.	2.4	59
50	â€œIt Is Definitely a Game Changerâ€: A Qualitative Study of Experiences with In-home Overnight Closed-Loop Technology Among Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 410-416.	2.4	28
51	Overcoming clinical inertia in insulin initiation in primary care for patients with type 2 diabetes: 24-month follow-up of the Stepping Up cluster randomised controlled trial. Primary Care Diabetes, 2017, 11, 474-481.	0.9	16
52	Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. BMJ: British Medical Journal, 2017, 356, j783.	2.4	46
53	Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report. Diabetes Care, 2016, 39, 1175-1179.	4.3	195
54	Peripheral neuropathy in the hands of people with diabetes mellitus. Diabetes Research and Clinical Practice, 2016, 119, 23-31.	1.1	16

#	Article	IF	Citations
55	Insulin pump basal adjustment for exercise in type 1 diabetes: a randomised crossover study. Diabetologia, 2016, 59, 1636-1644.	2.9	66
56	Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study. Diabetes Technology and Therapeutics, 2016, 18, 772-783.	2.4	77
57	Feasibility of an Orthogonal Redundant Sensor incorporating Optical plus Redundant Electrochemical Glucose Sensing. Journal of Diabetes Science and Technology, 2016, 10, 679-688.	1.3	7
58	Willingness to initiate insulin among adults with type 2 diabetes in Australian primary care: Results from the Stepping Up Study. Diabetes Research and Clinical Practice, 2016, 114, 126-135.	1.1	16
59	Redundancy in Glucose Sensing. Journal of Diabetes Science and Technology, 2016, 10, 669-678.	1.3	14
60	Optimizing Care and Outcomes for People with Type 2 Diabetes Ã¢â‚¬â€œ Lessons from a Translational Research Program on Insulin Initiation in General Practice. Frontiers in Medicine, 2015, 1, 60.	1.2	4
61	Plasma semicarbazide-sensitive amine oxidase activity in type 1 diabetes is related to vascular and renal function but not to glycaemia. Diabetes and Vascular Disease Research, 2014, 11, 262-269.	0.9	10
62	An exploratory trial of basal and prandial insulin initiation and titration for type 2 diabetes in primary care with adjunct retrospective continuous glucose monitoring: INITIATION study. Diabetes Research and Clinical Practice, 2014, 106, 247-255.	1.1	22
63	Feasibility of Adjacent Insulin Infusion and Continuous Glucose Monitoring via the Medtronic Combo-Set. Journal of Diabetes Science and Technology, 2013, 7, 381-388.	1.3	14
64	Increased serum kallistatin levels in type 1 diabetes patients with vascular complications. Journal of Angiogenesis Research, 2010, 2, 19.	2.9	38
65	Evaluation of an Algorithm to Guide Patients With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion on How to Respond to Real-Time Continuous Glucose Levels: A randomized controlled trial. Diabetes Care, 2010, 33, 1242-1248.	4.3	25
66	Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia. Medical Journal of Australia, 2009, 190, 552-556.	0.8	7
67	Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia, 2009, 52, 1250-1257.	2.9	194
68	Australian Aboriginal people and Torres Strait Islanders have an atherogenic lipid profile that is characterised by low HDL-cholesterol level and small LDL particles. Atherosclerosis, 2008, 201, 368-377.	0.4	25
69	Longitudinal analysis of low-molecular weight fluorophores in type 1 diabetes mellitus. Journal of Medical Investigation, 2008, 55, 29-36.	0.2	5
70	The role of continuous glucose monitoring in clinical decision-making in diabetes in pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2007, 47, 186-190.	0.4	65
71	Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. American Journal of Clinical Nutrition, 2000, 71, 1085-1094.	2.2	513
72	Diabetic Dyslipidaemia. Drugs, 2000, 59, 1101-1111.	4.9	35

#	Article	IF	Citations
73	The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis.. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 975-983.	1.8	96
74	Snapshot of CGM metrics in adolescents and adults achieving target HbA1c versus those not meeting target HbA1c.. Diabetes Technology and Therapeutics, 0, , .	2.4	0